Posted by Michael Wonder on 08 Aug 2022
Mayne Pharma and Mithra announce FDA approval of Haloette, a generic version of Nuvaring
8 August 2022 - Mayne Pharma and Mithra Pharmaceuticals are pleased to announce that the U.S. FDA has granted approval of the abbreviated new drug application for Haloette (etonogestrel and ethinyl estradiol) vaginal hormonal contraceptive ring.
Mayne Pharma anticipates the commercial launch of Haloette ring by early calendar year 2023.
